A naturopathic approach to the prevention of cardiovascular disease: Cost-effectiveness analysis of a pragmatic multi-worksite randomized clinical trial

Journal of Occupational and Environmental Medicine

Volumn 56, Issue 2, 2014, Pages 171-176

  Herman, Patricia M ^a   Szczurko, Orest ^b,c   Cooley, Kieran ^b,c   Seely, Dugald ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b CANADIAN COLLEGE OF NATUROPATHIC MEDICINE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; CANADA; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DIET THERAPY; DIRECTIVE COUNSELING; FEMALE; HEALTH CARE COSTS; HEALTH PROMOTION; HUMANS; MALE; MIDDLE AGED; NATUROPATHY; OCCUPATIONAL HEALTH SERVICES; PRIMARY PREVENTION; QUALITY-ADJUSTED LIFE YEARS; RISK REDUCTION BEHAVIOR;

EID: 84894083603     PISSN: 10762752     EISSN: 15365948     Source Type: Journal    
DOI: 10.1097/JOM.0000000000000066     Document Type: Article

References (29)

1. Centers for Disease Control and Prevention. Leading causes of death. Fast - Stats. Washington, DC: Centers for Disease Control and Prevention; 2007.
2. Statistics Canada. Leading Causes of Death. Statistics Canada; 2006.
3. Public Health Agency of Canada. Tracking heart disease and stroke in Canada. In: Public Health Agency of Canada, Canadian Institute for Health Information, Canadian Stroke Network, Heart and Stroke Foundation of Canada, Statistics Canada, eds. Ottawa, Ontario: Public Health Agency of Canada; 2009:132.
4. American Heart Association. Heart Disease and Stroke Statistics-2010 Update. Dallas, TX: American Heart Association; 2010.
5. Kahn R, Robertson RM, Smith R, Eddy D. The impact of prevention on reducing the burden of cardiovascular disease. Diabetes Care. 2008;31:1686-1696.
6. Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol. 2005;46:1225-1228. (Pubitemid 41615541)
7. Murray MT, Pizzorno JE. Naturopathic Medicine. In: Jonas WG, Levin JS, eds. Essentials of Complementary and Alternative Medicine. Philadelphia, PA: Lippincott Williams and Wilkins; 1999:304-321.
8. Fleming SA, Gutknecht NC. Naturopathy and the primary care practice. Prim Care Clin Office Pract. 2010;37:119-136.
9. Smith MJ, Logan AC. Naturopathy. Med Clin North Am. 2002;86:173-184. (Pubitemid 34028005)
10. Boon HS, Cherkin DC, Erro J, et al. Practice patterns of naturopathic physicians: results from a random survey of licensed practitioners in two US States. BMC Complement Altern Med. 2004;4:14.
11. Seely D, Szczurko O, Cooley K, et al. Naturopathic medicine for the prevention of cardiovascular disease: a randomized clinical trial. Can Med Assoc J. 2013;185:E409-E416.
12. Kessler RC, Catherine Barber MPA, Beck A, et al. The World Health Organization Health and Work Performance Questionnaire (HPQ). J Occup Environ Med. 2003;45:156.
13. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21:271-292. (Pubitemid 34143147)
14. D'Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743-753. (Pubitemid 351640675)
15. Anderson KM, Odel PM, Wilson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1991;121:293-298.
16. Briggs A, Clark T, Wolstenholme J, Clarke P. Missing⋯ presumed at random: cost-analysis of incomplete data. Health Econ. 2003;12:377-392. (Pubitemid 36603549)
17. McKnight PE, McKnight KM, Sidani S, Figueredo AJ. Missing Data: A Gentle Introduction. New York, NY: The Guilford Press; 2007.
18. Barber JA, Thompson SG. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med. 2000;19:3219-3236.
19. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. Boca Raton, FL: Chapman and Hall/CRC; 1994.
20. Drummond MF, Sculpher MJ, Torrance GW, O'Brien B, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press; 2005.
21. Franco OH, der Kinderen AJ, De Laet C, Peeters A, Bonneux L. Primary prevention of cardiovascular disease: cost-effectiveness comparison. Int J Technol Assess Health Care. 2007;23:71-79. (Pubitemid 46648302)
22. Wister A, Loewen N, Kennedy-Symonds H, McGowan B, McCoy B, Singer J. One-year follow-up of a therapeutic lifestyle intervention targeting cardiovascular disease risk. Can Med Assoc J. 2007;177:859-865. (Pubitemid 47612818)
23. Finkelstein EA, Troped PJ, Will JC, Palombo R. Cost-effectiveness of a cardiovascular disease risk reduction program aimed at financially vulnerable women: the Massachusetts WISEWOMAN project. J Womens Health Gender Based Med. 2002;11:519-526.
24. Eriksson MK, Hagberg L, Lindholm L, Malmgren-Olsson E-B, Osterlind J, Eliasson M. Quality of life and cost-effectiveness of a 3-year trial of lifestyle intervention in primary health care. Arch Intern Med. 2010;170:1470-1479.
25. Tran YBL, Frial T, Miller PSJ. Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins. Can J Clin Pharmacol. 2008;14:e205-e214. (Pubitemid 47324703)
26. Goetzel RZ, Long SR, Ozminkowski RJ, Hawkins K, Wang S, Lynch W. Health, absence, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting U. S. employers. J Occup Environ Med. 2003;46:398-412.
27. Mills PR, Kessler RC, Cooper J, Sullivan S. Impact of a health promotion program on employee health risks and work productivity. Am J Public Health. 2007;22:45-53. (Pubitemid 350194754)
28. Brindle P, Beswick A, Fahey T, Ebrahim S. Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. Heart. 2006;92:1752-1759. (Pubitemid 44851316)
29. Grover SA, Hemmelgarn B, Joseph L, Milot A, Tremblay G. The role of global risk assessment in hypertension therapy. Can J Cardiol. 2006;22:606-613. (Pubitemid 44044217)